Ali Yılmaz1, Cem Mirili2, Mehmet Bilici2, Salim Başol Tekin2. 1. Department of Medical Oncology, Atatürk University Faculty of Medicine, 25100, Erzurum, Turkey. draliyilmaz-h@hotmail.com. 2. Department of Medical Oncology, Atatürk University Faculty of Medicine, 25100, Erzurum, Turkey.
Abstract
BACKGROUND: It is known that colorectal cancers (CRC) are frequently seen and constitute an important part of cancer-related deaths. Lynch syndrome (LS) is responsible for 3-5% of CRCs and develops due to mutations in DNA mismatch repair (MMR) genes. The most important MMR genes are MutL homolog1 (MLH1), mutS homolog 2 (MSH2), mutS homolog 6 (MSH6) and postmeiotic segregation increased 2 (PMS2). PMS2 and MSH6 mutations are very rarely seen in LS. CASE PRESENTATION: We present a case that developed metastatic CRC, which we diagnosed as LS in association with a very rarely seen PMS2 and MSH6 germline mutation. Genetic counseling was recommended for the family, and screening programs were initiated for the family of the patient whose chemotherapy was continued after the diagnosis. CONCLUSION: With the increase in daily use of next-generation sequencing (NGS) technology, it is thought that detection rate of both combined mutations and rare mutations will be increased.
BACKGROUND: It is known that colorectal cancers (CRC) are frequently seen and constitute an important part of cancer-related deaths. Lynch syndrome (LS) is responsible for 3-5% of CRCs and develops due to mutations in DNA mismatch repair (MMR) genes. The most important MMR genes are MutL homolog1 (MLH1), mutS homolog 2 (MSH2), mutS homolog 6 (MSH6) and postmeiotic segregation increased 2 (PMS2). PMS2 and MSH6 mutations are very rarely seen in LS. CASE PRESENTATION: We present a case that developed metastatic CRC, which we diagnosed as LS in association with a very rarely seen PMS2 and MSH6 germline mutation. Genetic counseling was recommended for the family, and screening programs were initiated for the family of the patient whose chemotherapy was continued after the diagnosis. CONCLUSION: With the increase in daily use of next-generation sequencing (NGS) technology, it is thought that detection rate of both combined mutations and rare mutations will be increased.
Authors: Marco Agostini; Maria Grazia Tibiletti; Emanuela Lucci-Cordisco; Annamaria Chiaravalli; Hans Morreau; Daniela Furlan; Luigi Boccuto; Salvatore Pucciarelli; Carlo Capella; Mauro Boiocchi; Alessandra Viel Journal: Am J Gastroenterol Date: 2005-08 Impact factor: 10.864
Authors: Julie A Douglas; Stephen B Gruber; Karen A Meister; Joseph Bonner; Patrice Watson; Anne J Krush; Henry T Lynch Journal: JAMA Date: 2005-11-02 Impact factor: 56.272
Authors: E Lucci-Cordisco; V Rovella; S Carrara; A Percesepe; M Pedroni; A Bellacosa; O Caluseriu; M Forasarig; M Anti; G Neri; M Ponz de Leon; A Viel; M Genuardi Journal: Fam Cancer Date: 2001 Impact factor: 2.375
Authors: Sanne W Ten Broeke; Heleen M van der Klift; Carli M J Tops; Stefan Aretz; Inge Bernstein; Daniel D Buchanan; Albert de la Chapelle; Gabriel Capella; Mark Clendenning; Christoph Engel; Steven Gallinger; Encarna Gomez Garcia; Jane C Figueiredo; Robert Haile; Heather L Hampel; John L Hopper; Nicoline Hoogerbrugge; Magnus von Knebel Doeberitz; Loic Le Marchand; Tom G W Letteboer; Mark A Jenkins; Annika Lindblom; Noralane M Lindor; Arjen R Mensenkamp; Pål Møller; Polly A Newcomb; Theo A M van Os; Rachel Pearlman; Marta Pineda; Nils Rahner; Egbert J W Redeker; Maran J W Olderode-Berends; Christophe Rosty; Hans K Schackert; Rodney Scott; Leigha Senter; Liesbeth Spruijt; Verena Steinke-Lange; Manon Suerink; Stephen Thibodeau; Yvonne J Vos; Anja Wagner; Ingrid Winship; Frederik J Hes; Hans F A Vasen; Juul T Wijnen; Maartje Nielsen; Aung Ko Win Journal: J Clin Oncol Date: 2018-08-30 Impact factor: 50.717
Authors: Monika Vyas; Canan Firat; Jaclyn F Hechtman; Martin R Weiser; Rona Yaeger; Chad Vanderbilt; Jamal K Benhamida; Ajaratu Keshinro; Liying Zhang; Peter Ntiamoah; Marco Gonzalez; Rebecca Andrade; Imane El Dika; Arnold J Markowitz; J Joshua Smith; Julio Garcia-Aguilar; Efsevia Vakiani; David S Klimstra; Zsofia K Stadler; Jinru Shia Journal: Fam Cancer Date: 2020-10-09 Impact factor: 2.446